|
 |
|
|
| |
Life Sciences Portfolio |
|
|
Exited Companies
|
|
|
|
| |
.gif) |
Cita
NeuroPharmaceuticals Inc.
Acquired by Vernalis PLC in December 2005, Cita developed and commercialized small molecule drug candidates for neurological diseases and disorders. |
|
|
|
 |
Kadmus
Pharmaceutical Ltd.
Kadmus develops therapeutics for pain,
obesity and other central nervous system
disorders. In May 2007, its main program
was purchased by Dutch biotech firm, Organon
BioSciences N.V. Now a part of Merck and Co. Inc. |
|
|
|
 |
LymphoSign
Inc.
LymphoSign developed a small molecule drug candidate, which directly targets cancer cells for leukemia and other forms of blood-related cancers. In August 2007, LymphoSign was sold to Aegera Therapeutics Inc. |
|
|
| |
 |
Targanta
Therapeutics (Ontario) Inc.
Targanta Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on developing
and commercializing novel antibacterial agents
to address life-threatening infections
for the hospital market. In 2009, Targanta was successfully sold to The Medicines Company. |
|
|
|
 |
Xceed
Molecular Inc.
Xceed is a molecular diagnostics company, providing scientists and clinical researchers with innovative systems to translate novel multiplex gene expression tests into routine clinical practice. The assets of Xceed Molecular were acquired by Axela Biosensors Inc. |
| |
|
| |
 |
VisualSonics Inc.
VisualSonics is the world’s leading developer of high-resolution, ultrasound based in-vivo micro-imaging systems, specifically designed for non-invasive pre-clinical research.VisualSonics was acquired by Sonosite, the market leader in hand held ultrasound imaging tools for the clinical market. |
| |
|
|
Current Portfolio
Investee Companies
|
|
|
|
|
| |
 |
Aegera
Oncology Inc.
Aegera is a clinical-stage biotechnology company that develops
drugs to treat cancer and other serious
diseases including pain
related to diabetes and other injuries. |
|
|
|
 |
Axela
Biosensors Inc.
Axela develops
technologies for protein detection,
characterization and monitoring for
use in life science, health and clinical
research. |
|
|
| |
 |
Cytochroma Canada
Inc.
Cytochroma is a clinical-stage biotechnology
firm, which develops proprietary products
to treat and prevent the clinical consequences
of vitamin D deficiency, with a specific
focus on chronic kidney disease and related
complications. |
|
|
|
 |
Interface
Biologics Inc.
Interface develops unique biomaterials
for the coating and manufacturing of
a new generation of medical devices to
improve compatibility, efficacy and safety. |
|
|
| |
 |
Trillium
Therapeutics Inc.
Trillium develops
therapies that restore balance to the
immune system for many conditions such
as autoimmune and inflammatory disorders
as well as cancer. |
|
|
|
 |
Zelos Therapeutics Inc.
Zelos is a biopharmaceutical company developing novel therapies for patients suffering from conditions responsive to parathyroid hormone-based therapeutics. The Company is in late-stage clinical development with Ostabolin-C™, a parathyroid hormone analogue designed to improve upon the safety and efficacy of current therapies in the large and rapidly growing osteoporosis market. |
|
|
| |
|
|
| |
|
|
|
|
|
 |
